盐酸缬更昔洛韦片要注意什么事项呢？

The main ingredient of the tablet is valganciclovir hydrochloride. It is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis. So, what are the precautions for taking Valganciclovir Hydrochloride Tablets?

1. The absolute bioavailability of Vansevir measured by ganciclovir is 10 times higher than that of ganciclovir capsules. Vancevir cannot replace ganciclovir capsules in a 1:1 ratio. Patients who were previously taking ganciclovir capsules and are switching to Vancevir tablets should be informed that there is a risk of overdose if they take Vancevir in excess of the prescribed dose.

2. It is recommended to monitor complete blood count and platelet count during treatment. For patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, it is recommended to use blood cell growth factor therapy and/or consider suspending medication.

3. For patients with renal insufficiency, the dose needs to be adjusted according to the creatinine clearance rate.

4. For patients undergoing hemodialysis (CrCl<10ml/min), no recommended dosage can be given. Therefore, Valganciclovir Hydrochloride Tablets cannot be used in such patients.

5. Convulsions, sedation, dizziness, ataxia, and/or confusion have been reported after the use of valganciclovir hydrochloride tablets and/or cyclovir. If these conditions occur, they may affect activities that require concentration, including the patient's ability to drive a car and operate machinery.

6. Convulsions have been reported in patients taking imipenem-cilastatin and ganciclovir together. Valganciclovir hydrochloride tablets should not be used concomitantly with Tylenol unless the possible benefits outweigh the potential risks.

7. Both zidovudine and valganciclovir hydrochloride tablets may cause neutropenia and anemia when used alone. Some patients may not tolerate the full dose of these two drugs.

8. When combined with valganciclovir hydrochloride tablets, the plasma concentration of didanosine may increase; therefore, patients should be closely monitored for didanosine toxicity.

9. Combining Vancevir with other drugs known to have bone marrow suppression or related to renal insufficiency may lead to increased toxicity.

10. Medication for pregnant and lactating women:

(1) Due to the rapid and large-scale conversion of valganciclovir into ganciclovir, studies on its reproductive toxicity have not been repeated. In animal experiments, ganciclovir caused reduced fertility and teratogenic effects.

(2) It is recommended that women of childbearing age use effective contraceptive measures during treatment. Male patients are advised to use barrier contraception during treatment with valganciclovir hydrochloride tablets and for at least 90 days after discontinuation of treatment. There are no safety data on valganciclovir hydrochloride tablets during human pregnancy. Pregnant women should avoid the use of valganciclovir hydrochloride tablets unless the benefits to the mother far outweigh the potential harm to the fetus.

(3) The effects of valganciclovir or cyclovir on perinatal and postpartum infant development have not been studied, but it must be considered that ganciclovir may be secreted into breast milk and cause serious adverse reactions in nursing infants. Therefore, when considering the possible benefit of the tablets to the nursing mother, a decision should be made whether to discontinue medication or breastfeeding.